Effect of LIK066 on Body Weight in Patients With Elevated Body Mass Index

Summary

A 12-week study to assess LIK066 effect on body weight in diabetics, prediabetics and normoglycemic patients with elevated body mass index (BMI)

Timeline

Start

2015-06-05

Primary completion

2016-04-04

Completion

2016-04-04

Outcome

Met primary endpoint

registry Part 1: LIK066 150 mg Once Daily (qd) vs Part 1: Placebo Once Daily; p <0.001; Mean Difference (Net) -5.70 (80% CI -6.52 to -4.87) NCT02470403 ↗

registry Part 1: LIK066 150 mg Once Daily (qd) vs Part 1 and 2 : Pooled Placebo; p <0.001; Mean Difference (Net) -1.83 (80% CI -2.16 to -1.51) NCT02470403 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	licogliflozin	Small molecule	50 mg	—
Subject	licogliflozin	Small molecule	75 mg	—
Subject	licogliflozin	Small molecule	150 mg	—

Indications